SBI Okasan Asset Management Co.Ltd. Purchases New Shares in Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• SBI Okasan Asset Management disclosed a new fourth-quarter stake in Arrowhead Pharmaceuticals, buying 36,500 shares worth about $2.54 million.
• Arrowhead reported a smaller-than-expected quarterly loss of ($0.93) per share, but revenue of $73.74 million was down sharply year over year and the company remains unprofitable.
• Analysts remain generally constructive, with an average rating of “Moderate Buy” and an average price target of $87.80, even as some insiders recently sold shares.

SBI Okasan Asset Management Co.Ltd. purchased a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 36,500 shares of the biotechnology company's stock, valued at approximately $2,541,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of ARWR. Tsfg LLC purchased a new position in Arrowhead Pharmaceuticals during the 4th quarter worth $25,000. iSAM Funds UK Ltd purchased a new position in Arrowhead Pharmaceuticals during the 3rd quarter worth $29,000. First Horizon Corp purchased a new position in Arrowhead Pharmaceuticals during the 4th quarter worth $32,000. WPG Advisers LLC grew its position in Arrowhead Pharmaceuticals by 384.8% during the 4th quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 431 shares during the last quarter. Finally, Hantz Financial Services Inc. grew its position in Arrowhead Pharmaceuticals by 177.1% during the 4th quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company's stock worth $49,000 after purchasing an additional 471 shares during the last quarter. 62.61% of the stock is owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ:ARWR opened at $79.05 on Friday. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 1.41. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $14.30 and a fifty-two week high of $82.26. The firm's fifty day simple moving average is $69.14 and its 200-day simple moving average is $64.30. The stock has a market cap of $11.13 billion, a PE ratio of -36.77 and a beta of 1.28.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.93) EPS for the quarter, beating the consensus estimate of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The firm had revenue of $73.74 million during the quarter, compared to analysts' expectations of $73.84 million. During the same quarter last year, the business earned $2.75 earnings per share. The business's revenue for the quarter was down 86.4% compared to the same quarter last year. Analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.98 earnings per share for the current fiscal year.

Insider Activity at Arrowhead Pharmaceuticals

In related news, insider James C. Hamilton sold 10,000 shares of the firm's stock in a transaction dated Thursday, April 23rd. The shares were sold at an average price of $75.00, for a total value of $750,000.00. Following the completion of the sale, the insider owned 226,958 shares in the company, valued at $17,021,850. This trade represents a 4.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Hongbo Lu sold 2,970 shares of the firm's stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total transaction of $228,333.60. Following the completion of the sale, the director owned 52,012 shares of the company's stock, valued at $3,998,682.56. This trade represents a 5.40% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 36,065 shares of company stock worth $2,554,562 over the last 90 days. Company insiders own 3.60% of the company's stock.

Wall Street Analyst Weigh In

ARWR has been the topic of several research reports. JPMorgan Chase & Co. initiated coverage on shares of Arrowhead Pharmaceuticals in a research report on Friday, May 1st. They set an "overweight" rating and a $88.00 price objective on the stock. Weiss Ratings downgraded shares of Arrowhead Pharmaceuticals from a "hold (c-)" rating to a "sell (d-)" rating in a research report on Wednesday, May 20th. Sanford C. Bernstein upped their price objective on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a "market perform" rating in a research report on Wednesday, May 13th. Morgan Stanley upgraded shares of Arrowhead Pharmaceuticals from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $78.00 to $100.00 in a research report on Tuesday, April 21st. Finally, Royal Bank Of Canada upped their price objective on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an "outperform" rating in a research report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Arrowhead Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $87.80.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.